ANTIFIBROTIC EFFECT OF COMBINATION DAPAGLIFLOSIN AND METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE

Authors

  • Zemlianitsyna O. V. SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, UkraineP

DOI:

https://doi.org/10.21856/j-PEP.2019.2.04

Keywords:

diabetes mellitus, nonalcoholic fatty liver disease, hepatic fibrosis, scales for evaluation of level of fibrosis, treatment

Abstract

45 patients with type 2 diabetes mellitus and NAFLD (27 males and 18 females) were examined. The therapy included dietary recommendations, administration of oral hypoglycaemic agents: dapaglyphosin in a daily dose of 10 mg and metformin in a daily dose of 1500–2000 mg, 7 patients were additionally prescribed insulin. The efficacy of the combination of dapaglyphosin and metformin for the treatment of patients with type 2 diabe­tes mellitus and NAFLD was shown. Improvement of carbohydrate metabolism, reduction of BMI and improve­ment of liver synthetic function were observed on the background of long-term administration of these drugs. A decrease of these patients liver fibrosis degree was found, which is confirmed by noninvasive markers of fibro­sis, diagnostic indices and scales. The NAFLD scale was the most sensitive in diagnosis of liver fibrosis degree. Detection of a sufficiently large number of patients, the results of which can’t be unequivocally interpreted as the presence or absence of the risk of developing liver fibrosis, necessitates the development of another, more sensitive integrated scale that takes into account the features of the course of type 2 diabetes and contributed to reducing the direction of patients with liver biopsy for more a thorough diagnosis of the degree of fibrosis of this organ.

References

LaBrecque D, Abbas Z, Anania F, et al. J Clin Gastroenterol 2014; 48 (6): 467-473. https://doi.org/10.1097/MCG.0000000000000116.

Bakulin IG, Sandler JuG, Vinnickaja EV, et al. Terapevtich Arh 2017; 89 (2): 59-65.

Hall AR, Dhillon AP, Green AC, et al. Liver Int 2013; 33 (6): 926-935. https://doi.org/10.1111/liv.12162.

Buzzetti E, Pinzani M, Tsochatzis EA. Metabolism 2016; 65 (8): 1038-1048. https://doi.org/10.1016/j.metabol.2015.12.012.

Angulo P, Hui JM, Marchesini G, et al. Hepatology 2007; 45 (4): 846-854. https://doi.org/10.1002/hep.21496.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes

(EASD), European Association for the Study of Obesity(EASO). J Hepatol 2016;64(6): 1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004.

Chalasani N, Younossi Z, Lavine JE, et al. Am J Gastroenterol 2012; 107: 811-826. https://doi.org/10.1038/ajg.2012.128.

Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Eur J Pharmacol 2015; 754: 19-24. https://doi.org/10.1016/j.ejphar. 2015.02.009.

Koutsovasilis A, Sotiropoulos A, Blesta E, et al. EASD Meeting: abstract, 11–15 September 2017, Lisbon.

Tobita H, Sato S, Miyake T, et al. Curr Ther Res 2017; 87: 13-19. https://doi.org/10.1016/j.curtheres.2017.07.002.

Kamyshnikov VS. Spravochnik po kliniko-biohimicheskim issledovanijam i laboratornoj diagnostike. 3-e izd, Moskva, 2009: 896 p.

Sterling RK, Lissen E, Clumeck N, et al. Hepatology 2006; 43: 1317-1325. https://doi.org/10.1002/hep.21178.

Lin ZH, Xin YN, Dong QJ, et al. Hepatology 2011; 53: 726-736. https://doi.org/10.1002/hep.24105.

Downloads

Published

2019-06-13

How to Cite

Земляніцина, . О. В. (2019). ANTIFIBROTIC EFFECT OF COMBINATION DAPAGLIFLOSIN AND METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND NON-ALCOHOLIC FATTY LIVER DISEASE. Problems of Endocrine Pathology, 68(2), 27-33. https://doi.org/10.21856/j-PEP.2019.2.04

Issue

Section

CLINICAL ENDOCRINOLOGY